1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Chronic Lymphocytic Leukemia market 2016-2020

Global Chronic Lymphocytic Leukemia market 2016-2020

  • June 2016
  • -
  • Infiniti Research Limited
  • -
  • 78 pages


About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
- Acute myeloid (or myelogenous) leukemia (AML)
- Chronic myeloid (or myelogenous) leukemia (CML)
- Acute lymphocytic (or lymphoblastic) leukemia (ALL)
- CLL

Technavio’s analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.


The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- F. Hoffman-La Roche
- AbbVie
- Teva Pharmaceuticals
- Gilead Sciences
- Novartis
- Johnson & Johnson


Other prominent vendors
- Altor BioScience
- Amgen
- Arno Therapeutics
- AstraZeneca
- Bellicum Pharmaceuticals
- Biogen
- BioLineRx
- Boston Biomedical
- Celgene
- Emergent BioSolutions
- Genzyme
- iDD biotech
- Immunomedics
- Infinity Pharmaceuticals
- Innate Pharma
- Karyopharm Therapeutics
- Ligand Pharmaceuticals
- MedImmune
- Merck Sharp & Dohme
- Molecular Templates Inc.
- MorphoSys
- Ono Pharmaceutical
- Portola Pharmaceuticals
- Regeneron Pharmaceuticals
- Sunesis Pharmaceuticals
- TG Therapeutics
- TheraMAB
- XEME Biopharma
- Xencor
- ZIOPHARM Oncology

Market driver
- Special regulatory designations
- For a full, detailed list, view our report

Market challenge
- High cost of therapy
- For a full, detailed list, view our report

Market trend
- Rise in development of combination therapies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Chronic Lymphocytic Leukemia market 2016-2020
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Disease overview
- Understanding the disease
- Types of CLL
- Symptoms
- Diagnosis
- Staging
- Management
- Key buying criteria
PART 06: Pipeline analysis
- Acalabrutinib
- TG-1101 + ibrutinib
- TGR-1202
- Venetoclax + obinutuzumab
- Venetoclax + rituximab
- REVLIMID
- Duvelisib
PART 07: Market landscape
- Global CLL therapeutics market
- Total addressable market for global CLL therapeutics
- Five forces analysis
PART 08: Market segmentation by ROA
- Oral
- Parenteral
PART 09: Market segmentation by type of molecule
- Small molecules
- Biologics
PART 10: Geographical segmentation
- Global CLL therapeutics market by geographical segmentation 2015-2020
- CLL therapeutics market in Americas
- CLL therapeutics market in EMEA
- CLL therapeutics market in APAC
PART 11: Market drivers
- Special regulatory designations
- Recent drug approvals
- Application for expanded indication approvals
- Increase in patient pool
PART 12: Impact of drivers
PART 13: Market challenges
- High cost of therapy
- Availability of chemotherapy and off-label drugs
- Adverse effects of drugs
- Stringent regulatory guidelines
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Joint ventures and partnerships
- Patient assistance programs
- Rise in development of combination therapies
- Growing public awareness
- PART 16: Vendor landscape
- Competitive scenario
- Market share analysis 2015
- F. Hoffmann-La Roche
- AbbVie
- Teva Pharmaceuticals
- Johnson and Johnson
- Gilead Sciences
- Novartis
- Other prominent vendors
PART 17: Appendix
- List of abbreviations
PART 18: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Timeline of development of leukemia drugs
Exhibit 03: Snapshot of CLL
Exhibit 04: Types of CLL
Exhibit 05: Main diagnostic procedures to determine presence of CLL
Exhibit 06: Other diagnostic procedures to determine presence of CLL
Exhibit 07: Rai stages of CLL
Exhibit 08: Binet stages of CLL
Exhibit 09: Management of CLL
Exhibit 10: Key buying criteria for CLL drugs
Exhibit 11: Pipeline portfolio: Global CLL therapeutics market
Exhibit 12: Percentage share of drug candidates by stage of development 2015
Exhibit 13: Global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 14: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 15: Five forces analysis
Exhibit 16: Segmentation of global CLL therapeutics market by ROA 2015
Exhibit 17: Segmentation of global CLL therapeutics market by type of molecule 2015
Exhibit 18: Segmentation of global CLL therapeutics market based on geography 2015
Exhibit 19: Segmentation of global CLL therapeutics market based on geography 2020
Exhibit 20: Global CLL therapeutics market by geography 2015-2020 ($ millions)
Exhibit 21: Global CLL therapeutics market by geography 2015-2020
Exhibit 22: CLL therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 23: CLL therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 24: CLL therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 25: Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 26: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 27: Impact of drivers
Exhibit 28: Cost of therapy for CLL
Exhibit 29: Impact of drivers and challenges
Exhibit 30: SWOT: MabThera
Exhibit 31: SWOT: Imbruvica
Exhibit 32: SWOT: Treanda
Exhibit 33: SWOT of Zydelig
Exhibit 34: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions)
Exhibit 35: MabThera/Rituxan geographic segmentation by revenue 2015
Exhibit 36: F. Hoffmann-La Roche: Key takeaways
Exhibit 37: AbbVie: Key takeaways
Exhibit 38: Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions)
Exhibit 39: Teva Pharmaceuticals: Key takeaways
Exhibit 40: Johnson and Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions)
Exhibit 41: Johnson and Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions)
Exhibit 42: Johnson and Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions)
Exhibit 43: Johnson and Johnson: Geographic segmentation of Imbruvica 2015
Exhibit 44: Johnson and Johnson: Key takeaways
Exhibit 45: Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions)
Exhibit 46: Gilead Sciences: Key takeaways
Exhibit 47: Novartis: Key takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.